article thumbnail

Injectable Angioplasty Balloon Catheter Transforms Peripheral Procedures, Users Report Reduced Equipment and Contrast Needs

DAIC

(Photo: Business Wire milla1cf Thu, 01/18/2024 - 14:05 January 18, 2024 — Summa Therapeutics, LLC announced that the first-in-man injectable angioplasty procedures for patients with below-knee peripheral arterial disease (PAD) were performed successfully using its Finesse Injectable balloon catheter platform. most due to circulation issues.

article thumbnail

Impact of Diabetes on Outcomes in Left Main Coronary Revascularization: PCI vs. CABG

Cardiology Update

Left main coronary artery disease (CAD) and diabetes pose significant challenges in cardiovascular care, often leading to adverse outcomes. Preliminary evidence from trials focusing on patients with multivessel disease has hinted at diabetes as a potential modifier of treatment outcomes.

Diabetes 122
article thumbnail

Trends in prognosis and use of SGLT2i and GLP-1 RA in patients with diabetes and coronary artery disease

Cardiovascular Diabetology

Objective To explore trends in prognosis and use of glucose-lowering drugs (GLD) in patients with diabetes and coronary artery disease (CAD). Research design and methods All patients with diabetes and CAD undergoing a coronary angiography between 2010 and 2021 according to the Swedish Angiography and Angioplasty Registry were included.

article thumbnail

Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With or Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials

Circulation

Patients were categorized by diabetes status. Kaplan-Meier event rates, Cox model hazard ratios, and interactions were assessed.RESULTS:Among 4393 patients, 1104 (25.1%) had diabetes. PintHR=0.87) diabetes. Patients were considered suitable for either approach. and 9.9%) compared with those without (2.1%

article thumbnail

Understanding the Difference Between Heart Attack and Cardiac Arrest

MIBHS

Seeking emergency medical attention can restore blood flow and prevent further damage.

article thumbnail

BIDMC-led Trial Leads to FDA approval of Coronary Drug-coated Balloons

DAIC

milla1cf Wed, 03/13/2024 - 16:52 March 13, 2024 — In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.

Stents 116
article thumbnail

Boston Scientific Receives FDA Approval for the AGENT Drug-Coated Balloon

DAIC

1,2 Serving as an alternative to traditional therapies such as balloon angioplasty, additional layers of stenting or radiation, the AGENT DCB is a paclitaxel-coated balloon catheter that transfers a therapeutic dose of drug to the vessel wall to help prevent ISR reoccurrence. vs. 28.7%; P=0.006). Treating ISR has been challenging in the U.S.

Stents 105